3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
7
Uterine Cervical Dysplasia
6
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Squamous Intraepithelial Lesions
1
Precancerous Conditions
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Barrett Esophagus
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Acetic Acid
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled